Company / SG&A per Share
Seres Therapeutics, Inc. SG&A per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$8.96
FY2025
5-year range
$0.27 / $8.96
FY2021-FY2025
Trend
+1519.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A per Share changed +1520% YoY in FY2025, a notable deviation from the 9-year average annual change of +206%.
Based on SEC 10-K filings.
8.96 in FY2025 with a 10-year CAGR of +47.7%.
Increased from $0.33 to $8.96 over the past 3 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +199.1%
- 5-Year CAGR
- +80.7%
- 10-Year CAGR
- +47.7%
Key checks
Key Insights
- Seres Therapeutics, Inc.'s sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 1519.8% year-over-year.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.96 | +1519.8% |
| FY2023 | $0.55 | +65.1% |
| FY2022 | $0.33 | +23.8% |
| FY2021 | $0.27 | -41.8% |
| FY2020 | $0.46 | -44.1% |
| FY2019 | $0.83 | +3.4% |
| FY2018 | $0.80 | +93.6% |
| FY2017 | $0.42 | +272.0% |
| FY2016 | $0.11 | -38.3% |
| FY2015 | $0.18 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026